top of page

Attovia Therapeutics raised a $105M series B today to take on the I&I space, including designing multi-target bispecifics

Founder & CEO Tao Fu walks us through the company's ATTOBODY platform and discusses programs targeting IL31 and IL31 x IL13.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page